Da Li

机构：Capital Medical University, Northeast Normal University, Beijing Tian Tan Hospital, National Clinical Research Center for Digestive Diseases, Ningbo No. 2 Hospital, Beijing Children’s Hospital, China Medical University · ORCID：0000-0003-0629-0742

发表论文 173 篇 · 总被引 2931 次 · h-index 24

代表论文

• Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study (2025 · The Lancet Oncology · 被引 25)
• Radiosurgery versus observation for brainstem cavernous malformations: a 5-year multicentre cohort study (2024 · Brain · 被引 6)
• Histone H3 Lysine 18 Lactylation Promotes Cardiac Hypertrophy Through Activating GATA Binding Protein 4 Signaling (2025 · MedComm · 被引 5)
• Identification of SLC7A1 as a potential therapeutic target for high-grade meningioma (2025 · Cell Death Discovery · 被引 4)
• Lifetime Risk of First Symptomatic ICH or Seizure in Familial Cerebral Cavernous Malformations (2025 · Neurology · 被引 3)
• A Review of the Mechanisms of Astragaloside IV and Berberine in Vascular Dysfunction Associated with Obesity and Diabetes (2025 · Drug Design Development and Therapy · 被引 3)